1. Antipass A, Austin A, Awad S, Hughes D, Idris I. Evaluation of liver function tests and risk score assessment to screen patients for significant liver disease prior to bariatric and metabolic surgery. Obes Surg 2020; 30(7): 2840-3.
2. Varbanova M, Maggard B, Lenhardt R. Preoperative preparation and premedication of bariatric surgical patient. Saudi J Anaesth 2022; 16(3): 287-98.
3. Zhao B, Zhang J, Zhang J, Zou S, Luo R, Xu H, et al. The impact of preoperative underweight status on postoperative complication and survival outcome of gastric cancer patients: a systematic review and meta-analysis. Nutr Cancer 2018; 70(8): 1254-63.
4. Shin CI, Kim SH. Normal and abnormal postoperative imaging findings after gastric oncologic and bariatric surgery. Korean J Radiol 2020; 21(7): 793-811.
5. Elnahas A, Nguyen GC, Okrainec A, Quereshy F, Jackson TD. The effect of underlying liver disease on short-term outcomes following bariatric surgery. Surg Endosc 2014; 28(9): 2708-12.
6. Benaiges D, Goday A, Pedro-Botet J, Más A, Chillarón JJ, Flores-Le Roux JA. Bariatric surgery: to whom and when? Minerva Endocrinol 2015 ;40(2):119-28.
7. Doulberis M, Srivastava S, Polyzos SA, Kountouras J, Papaefthymiou A, Klukowska-Rötzler J, et al. Active helicobacter pylori infection is independently associated with nonalcoholic steatohepatitis in morbidly obese patients. J Clin Med 2020; 9(4): 933.
8. Emile SH. Should We Test for and Eradicate Helicobacter pylori Before Bariatric Surgery? Obes Surg 2021; 31(4): 1841-2.
9. Geerts A, Darius T, Chapelle T, et al. The multicenter Belgian survey on liver -transplantation for hepatocellular failure after bariatric surgery. Transplant Proc 2010; 42(10): 4395-8.
10. Lefere S, Hoorens A, Raevens S, Troisi R, Verhelst X, van Vlierberghe H, et al. Refractory subacute steatohepatitis after biliopancreatic diversion. Hepatology 2017; 66(1): 289-91.
11. Cazzo E, Pareja JC, Chaim EA. Liver failure following biliopancreatic diversions: a narrative review. Sao Paulo Med J 2017; 135(1): 66-70.
12. Tao W, Santoni G, von Euler-Chelpin M, Ljung R, Lynge E, Pukkala E, et al. Cancer risk after bariatric surgery in a cohort study from the five nordic countries. Obes Surg 2020; 30(10): 3761-7.
13. Tao W, Artama M, von Euler-Chelpin M, Hull M, Ljung R, Lynge E, et al. Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study. Int J Cancer 2020; 147(3): 728-35.
14. Heimgartner B, Herzig M, Borbély Y, Kröll D, Nett P, Tutuian R. Symptoms, endoscopic findings and reflux monitoring results in candidates for bariatric surgery. Dig Liver Dis 2017; 49: 750-6.
15. Martín-Pérez J, Arteaga-González I, Martín-Malagón A, Díaz-Luis H, Casanova-Trujillo C, Carrillo-Pallarés AA. Frequency of abnormal esophageal acid exposure in patients eligible for bariatric surgery. Surg Obes Relat Dis 2014; 10(6): 1176-80.
16. D'Silva M, Bhasker AG, Kantharia NS, Lakdawala M. High-percentage pathological findings in obese patients suggest that sophagogastroduodenoscopy should be made mandatory prior to bariatric surgery. Obes Surg 2018; 28(9): 2753-9
17. Hansdotter I, Björ O, Andreasson A, Agreus L, Hellström P, Forsberg A, Talley NJ, Vieth M, Wallner B. Hill classification is superior to the axial length of a hiatal hernia for assessment of the mechanical anti-reflux barrier at the gastroesophageal junction. Endosc Int Open 2016; 4(3): E311-7.
18. Angulo P, Lindor KD. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346(16): 1221-31.
19. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370(14): 1287-97.
20. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7-30.
21. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K,Rinella M, et al. Clinical practice guidelines on the diagnosis and management of nonalcoholic fatty liver disease. Hepatology 2018; 67(1): 328-57.
22. Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol Sci 2024; 45(10): 892-903.